Claritev Responds to DOJ Criminal Antitrust Probe Allegations, Confirms Ongoing Investigation Since 2024
CTEV is trading near its 52-week low of $11.5 (1.8% above the low).
Summary
Claritev Corp filed an 8-K to address a news article alleging a criminal antitrust probe by the DOJ, confirming an ongoing investigation since August 2024 but stating it has not been informed it is a target.
Key Events · Legal and Risk Events · CTEV
-
DOJ Antitrust Probe Allegation
Claritev is responding to a May 14, 2026 article alleging a criminal antitrust probe by the Department of Justice.
-
Ongoing Investigation Confirmed
The company confirms it received a confidential grand jury subpoena from the DOJ in August 2024 regarding a health insurance investigation.
-
Not a Target (Company's Stance)
Claritev states the DOJ has not informed them that they are a target of the investigation in the two years since the subpoena.
-
Full Cooperation
The company asserts it has been fully cooperating with the DOJ.
Analysis · CTEV · Trade & Services
This filing addresses a serious legal and regulatory risk for Claritev Corp. While the company clarifies that the investigation has been ongoing since August 2024 and they have not been designated as a target, the public allegation of a "criminal antitrust probe" introduces significant uncertainty and potential for substantial legal costs and reputational damage. This comes at a challenging time, with the company reporting increased net losses and its stock trading near 52-week lows. Investors will be closely watching for any further updates on the DOJ investigation.
At the time of this filing, CTEV was trading at $11.71 on NYSE in the Trade & Services sector, with a market capitalization of approximately $199.6M. The 52-week trading range was $11.50 to $74.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.